Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07407894

iVS-1 Probiotic Intervention Targeting Biological Aging in Midlife Adults

VITAL-Age Trial (iVS-1 Investigation for Targeting Aging and Longevity)

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
80 (estimated)
Sponsor
Synbiotic Health · Industry
Sex
All
Age
40 Years – 75 Years
Healthy volunteers
Accepted

Summary

This study is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of Bifidobacterium adolescentis (iVS-1) supplementation on biological aging markers, metabolic health, and functional health outcomes in midlife adults. The study explores whether modulation of aging-related biological pathways through the gut microbiome may influence health-related outcomes.

Detailed description

Aging is associated with progressive physiological changes involving inflammation, cellular senescence, mitochondrial function, and alterations in the gut microbiome. Interventions targeting these biological processes may influence age-related health outcomes. The gut microbiome plays a central and modifiable role, influencing metabolic health, inflammation, neurocognitive outcomes, and systemic aging processes. Reductions in Bifidobacterium adolescentis have been observed with aging and have been associated with metabolic and inflammatory changes. Preliminary studies suggest that supplementation with this species may affect biological pathways relevant to aging. This study is a randomized, double-blind, placebo-controlled trial designed to evaluate the effects of Bifidobacterium adolescentis (iVS-1) supplementation in adults aged 40-75 years. Participants will be randomized to receive iVS-1 (≥8 billion CFU per capsule) or placebo once daily for 150 days. Blood- and stool-based assessments and questionnaires about cognition, sleep quality, and quality of life will be collected at baseline, mid-intervention, and end of study. Changes in these measures will be used to assess the relationship between Bifidobacterium adolescentis iVS-1 supplementation and biological aging markers, metabolic health, and functional health outcomes.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTBifidobacterium adolescentis iVS-1B. adolescentis iVS-1 (probiotic capsule) delivered orally once daily at a minimum of 8 billion CFU/day
DIETARY_SUPPLEMENTPlaceboPlacebo capsule delivered orally once daily

Timeline

Start date
2026-02-01
Primary completion
2027-01-01
Completion
2027-01-01
First posted
2026-02-12
Last updated
2026-02-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT07407894. Inclusion in this directory is not an endorsement.